Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro
Metabolic disorders are increasingly prevalent conditions that manifest pathophysiologically along a continuum. Among reported metabolic risk factors, elevated fasting serum glucose (FSG) levels have shown the most substantial increase in risk exposure. Ultimately leading to insulin resistance (IR),...
Published in: | Marine Drugs |
---|---|
Main Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
MDPI
2024
|
Subjects: | |
Online Access: | https://hdl.handle.net/11250/3127847 https://doi.org/10.3390/md22040151 |
id |
ftntnutrondheimi:oai:ntnuopen.ntnu.no:11250/3127847 |
---|---|
record_format |
openpolar |
spelling |
ftntnutrondheimi:oai:ntnuopen.ntnu.no:11250/3127847 2024-05-19T07:37:48+00:00 Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro Bjerknes, Christian Wubshet, Sileshi Gizachew Rønning, Sissel Beate Afseth, Nils Kristian Crawford, Currie Framroze, Bomi Hermansen, Erland 2024 application/pdf https://hdl.handle.net/11250/3127847 https://doi.org/10.3390/md22040151 eng eng MDPI Norges forskningsråd: 314111 Nofima AS: 202102 Norges forskningsråd: 314599 Nofima AS: 202101 Marine Drugs. 2024, 22 (4), 1-18. urn:issn:1660-3397 https://hdl.handle.net/11250/3127847 https://doi.org/10.3390/md22040151 cristin:2262806 Navngivelse 4.0 Internasjonal http://creativecommons.org/licenses/by/4.0/deed.no 1-18 22 Marine Drugs 4 Journal article Peer reviewed 2024 ftntnutrondheimi https://doi.org/10.3390/md22040151 2024-04-26T02:04:22Z Metabolic disorders are increasingly prevalent conditions that manifest pathophysiologically along a continuum. Among reported metabolic risk factors, elevated fasting serum glucose (FSG) levels have shown the most substantial increase in risk exposure. Ultimately leading to insulin resistance (IR), this condition is associated with notable deteriorations in the prognostic outlook for major diseases, including neurodegenerative diseases, cancer risk, and mortality related to cardiovascular disease. Tackling metabolic dysfunction, with a focus on prevention, is a critically important aspect for human health. In this study, an investigation into the potential antidiabetic properties of a salmon protein hydrolysate (SPH) was conducted, focusing on its potential dipeptidyl peptidase-IV (DPP-IV) inhibition and direct glucose uptake in vitro. Characterization of the SPH utilized a bioassay-guided fractionation approach to identify potent glucoregulatory peptide fractions. Low-molecular-weight (MW) fractions prepared by membrane filtration (MWCO = 3 kDa) showed significant DPP-IV inhibition (IC50 = 1.01 ± 0.12 mg/mL) and glucose uptake in vitro (p ≤ 0.0001 at 1 mg/mL). Further fractionation of the lowest MW fractions (<3 kDa) derived from the permeate resulted in three peptide subfractions. The subfraction with the lowest molecular weight demonstrated the most significant glucose uptake activity (p ≤ 0.0001), maintaining its potency even at a dilution of 1:500 (p ≤ 0.01). publishedVersion Article in Journal/Newspaper Atlantic salmon Salmo salar NTNU Open Archive (Norwegian University of Science and Technology) Marine Drugs 22 4 151 |
institution |
Open Polar |
collection |
NTNU Open Archive (Norwegian University of Science and Technology) |
op_collection_id |
ftntnutrondheimi |
language |
English |
description |
Metabolic disorders are increasingly prevalent conditions that manifest pathophysiologically along a continuum. Among reported metabolic risk factors, elevated fasting serum glucose (FSG) levels have shown the most substantial increase in risk exposure. Ultimately leading to insulin resistance (IR), this condition is associated with notable deteriorations in the prognostic outlook for major diseases, including neurodegenerative diseases, cancer risk, and mortality related to cardiovascular disease. Tackling metabolic dysfunction, with a focus on prevention, is a critically important aspect for human health. In this study, an investigation into the potential antidiabetic properties of a salmon protein hydrolysate (SPH) was conducted, focusing on its potential dipeptidyl peptidase-IV (DPP-IV) inhibition and direct glucose uptake in vitro. Characterization of the SPH utilized a bioassay-guided fractionation approach to identify potent glucoregulatory peptide fractions. Low-molecular-weight (MW) fractions prepared by membrane filtration (MWCO = 3 kDa) showed significant DPP-IV inhibition (IC50 = 1.01 ± 0.12 mg/mL) and glucose uptake in vitro (p ≤ 0.0001 at 1 mg/mL). Further fractionation of the lowest MW fractions (<3 kDa) derived from the permeate resulted in three peptide subfractions. The subfraction with the lowest molecular weight demonstrated the most significant glucose uptake activity (p ≤ 0.0001), maintaining its potency even at a dilution of 1:500 (p ≤ 0.01). publishedVersion |
format |
Article in Journal/Newspaper |
author |
Bjerknes, Christian Wubshet, Sileshi Gizachew Rønning, Sissel Beate Afseth, Nils Kristian Crawford, Currie Framroze, Bomi Hermansen, Erland |
spellingShingle |
Bjerknes, Christian Wubshet, Sileshi Gizachew Rønning, Sissel Beate Afseth, Nils Kristian Crawford, Currie Framroze, Bomi Hermansen, Erland Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
author_facet |
Bjerknes, Christian Wubshet, Sileshi Gizachew Rønning, Sissel Beate Afseth, Nils Kristian Crawford, Currie Framroze, Bomi Hermansen, Erland |
author_sort |
Bjerknes, Christian |
title |
Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
title_short |
Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
title_full |
Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
title_fullStr |
Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
title_full_unstemmed |
Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon (Salmo salar): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro |
title_sort |
glucoregulatory properties of a protein hydrolysate from atlantic salmon (salmo salar): preliminary characterization and evaluation of dpp-iv inhibition and direct glucose uptake in vitro |
publisher |
MDPI |
publishDate |
2024 |
url |
https://hdl.handle.net/11250/3127847 https://doi.org/10.3390/md22040151 |
genre |
Atlantic salmon Salmo salar |
genre_facet |
Atlantic salmon Salmo salar |
op_source |
1-18 22 Marine Drugs 4 |
op_relation |
Norges forskningsråd: 314111 Nofima AS: 202102 Norges forskningsråd: 314599 Nofima AS: 202101 Marine Drugs. 2024, 22 (4), 1-18. urn:issn:1660-3397 https://hdl.handle.net/11250/3127847 https://doi.org/10.3390/md22040151 cristin:2262806 |
op_rights |
Navngivelse 4.0 Internasjonal http://creativecommons.org/licenses/by/4.0/deed.no |
op_doi |
https://doi.org/10.3390/md22040151 |
container_title |
Marine Drugs |
container_volume |
22 |
container_issue |
4 |
container_start_page |
151 |
_version_ |
1799477169816076288 |